838 related articles for article (PubMed ID: 27079249)
21. Improving pediatric dosing through pediatric initiatives: what we have learned.
Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
[TBL] [Abstract][Full Text] [Related]
22. Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.
Wang J; Edginton AN; Avant D; Burckart GJ
J Clin Pharmacol; 2015 Oct; 55(10):1175-83. PubMed ID: 25907280
[TBL] [Abstract][Full Text] [Related]
23. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization.
Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L
Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287
[TBL] [Abstract][Full Text] [Related]
24. Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures.
Nielsen JC; Hutmacher MM; Wesche DL; Tolbert D; Patel M; Kowalski KG
J Clin Pharmacol; 2015 Jan; 55(1):81-92. PubMed ID: 25117853
[TBL] [Abstract][Full Text] [Related]
25. Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children.
Ince I; Dallmann A; Frechen S; Coboeken K; Niederalt C; Wendl T; Block M; Meyer M; Eissing T; Burghaus R; Lippert J; Willmann S; Schlender JF
J Clin Pharmacol; 2021 Jun; 61 Suppl 1(Suppl 1):S70-S82. PubMed ID: 34185905
[TBL] [Abstract][Full Text] [Related]
26. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
28. Pediatric critical care pharmacodynamics.
Dionne R; McManus C
Crit Care Nurs Clin North Am; 1993 Jun; 5(2):367-75. PubMed ID: 8398042
[TBL] [Abstract][Full Text] [Related]
29. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
31. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
32. Pediatric Dose Selection and Utility of PBPK in Determining Dose.
Templeton IE; Jones NS; Musib L
AAPS J; 2018 Feb; 20(2):31. PubMed ID: 29441439
[TBL] [Abstract][Full Text] [Related]
33. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
[TBL] [Abstract][Full Text] [Related]
34. Failed Pediatric Drug Development Trials.
Momper JD; Mulugeta Y; Burckart GJ
Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
[TBL] [Abstract][Full Text] [Related]
35. Pharmacometric Bridging Approach for U.S. Food and Drug Administration Approval and Identification of Topiramate Dosing Regimen for Pediatric Patients 2-9 Years of Age With Epilepsy.
Marathe A; Liu C; Kapcala LP; Hershkowitz N; Men A; Uppoor R; Mehta M; Wang Y
J Pharm Sci; 2019 Apr; 108(4):1598-1603. PubMed ID: 30468826
[TBL] [Abstract][Full Text] [Related]
36. Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.
Elmorsi Y; Barber J; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Jul; 44(7):992-8. PubMed ID: 26712821
[TBL] [Abstract][Full Text] [Related]
37. Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration.
Zhang Y; Wang Y; Khurana M; Sachs HC; Zhu H; Burckart GJ; Alexander J; Yao LP; Wang J
Clin Pharmacol Ther; 2020 Jul; 108(1):90-98. PubMed ID: 32030741
[TBL] [Abstract][Full Text] [Related]
38. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
[TBL] [Abstract][Full Text] [Related]
39. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
Xu Y; Langevin BA; Zhou H; Xu Z
J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
[TBL] [Abstract][Full Text] [Related]
40. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
Rostami-Hodjegan A
Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
